KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) had its price objective increased by HC Wainwright from $20.00 to $27.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the specialty pharmaceutical company's stock. HC Wainwright's target price indicates a potential upside of 85.95% from the company's previous close. HC Wainwright also issued estimates for KalVista Pharmaceuticals' Q4 2025 earnings at ($0.35) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $1.62 EPS, FY2029 earnings at $3.37 EPS and FY2030 earnings at $4.08 EPS.
A number of other research analysts also recently issued reports on KALV. Leerink Partners boosted their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday. Needham & Company LLC restated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, Jones Trading restated a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $26.29.
Get Our Latest Research Report on KALV
KalVista Pharmaceuticals Stock Down 6.4%
Shares of NASDAQ KALV traded down $0.99 during midday trading on Tuesday, reaching $14.52. The company had a trading volume of 2,085,829 shares, compared to its average volume of 572,165. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $16.32. The firm's fifty day moving average price is $12.57 and its 200-day moving average price is $11.23. The stock has a market cap of $721.93 million, a PE ratio of -3.93 and a beta of -0.04.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter in the prior year, the company earned ($1.07) earnings per share. As a group, equities research analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current year.
Insider Buying and Selling
In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,776 shares of the company's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the transaction, the insider owned 106,611 shares in the company, valued at approximately $1,262,274.24. This represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 32,979 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total value of $517,440.51. Following the completion of the sale, the chief executive officer directly owned 369,595 shares in the company, valued at approximately $5,798,945.55. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 48,878 shares of company stock worth $723,617 in the last quarter. Company insiders own 10.50% of the company's stock.
Institutional Trading of KalVista Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its position in shares of KalVista Pharmaceuticals by 3.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock worth $3,923,000 after purchasing an additional 12,263 shares in the last quarter. Rhumbline Advisers boosted its position in shares of KalVista Pharmaceuticals by 3.4% in the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock worth $611,000 after purchasing an additional 1,762 shares in the last quarter. Woodline Partners LP boosted its position in shares of KalVista Pharmaceuticals by 25.5% in the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock worth $18,666,000 after purchasing an additional 329,068 shares in the last quarter. Parkman Healthcare Partners LLC bought a new stake in shares of KalVista Pharmaceuticals in the 1st quarter worth approximately $8,698,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of KalVista Pharmaceuticals by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock worth $281,000 after purchasing an additional 2,939 shares in the last quarter.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Further Reading

Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.